Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Neutral 50.7%

Neg 0% Neu 50.7% Pos 0%

Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.